Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

A LARGE-SCALE MICROFLUIDICS IMAGING PLATFORM FOR HIGH-THROUGHPUT TOXICITY TESTING USING CANINE INTESTINAL ORGANOIDS

Export to Word (http://www.niehs.nih.gov//portfolio/index.cfm/portfolio/grantdetail/grant_number/R43ES029890/format/word)
Principal Investigator: Hegarty, Evan
Institute Receiving Award Newormics, Llc
Location Austin, TX
Grant Number R43ES029890
Funding Organization National Institute of Environmental Health Sciences
Award Funding Period 01 Jun 2019 to 31 May 2021
DESCRIPTION (provided by applicant): Project Summary: Currently, toxicology studies require a large number of animal testing to identify better and safer drug candidates. In an attempt to reduce the use of large animals in pharmaceutical industry, there is a need to bridge the gap between the conventional in vitro cell-based assay and the non-human animal studies. Recently, three- dimensional models are gaining momentum and replacing conventional 2D cell culture assay. 3D organoids derived from animals can serve the purpose of drug testing recapitulating the drug effect in the whole animal. Organoids derived from dog, with many shared disease pathophysiology, is advantageous since multiple biopsy samples can be operated without sacrificing the animal, allowing longitudinal observation of the same animal under the disease pathology. Dog spontaneously develops cancer with similar clinical pathology appearance, therapeutic responses, and acquired resistance to treatments, similar to that in human. Growing and investigating 3D organoids in large quantities from fresh and frozen biopsy samples are pivotal roles in implementing the large-scale screening approach using the organoid-based approach. In order to image a large number of organoids for high-throughput phenotypic screens, we will pursue our goals in two specific aims: 1) we will develop the microfluidic device and characterize the culturing, and 2) perform dose-dependent toxicity test by treating the enteroids and coloinds with doxorubicin, an intravenous (IV) chemotherapy agent. In Aim 1.1, we will design a new microfluidic platform to immobilize and image ten organoids from eight different populations using a confocal microscope. The specific geometry of the chip will immobilize the organoids completely in an optically favorable orientation while eliminating motion blur during stage motion to move the samples. In Aim 1.2 we will characterize the growth and physiological states of the two organoids (enterdoids and colonoids) using multiple passages from both fresh and frozen tissue samples. On the successful characterization of the cultures and the imaging method, the organoids will be evaluated for dose toxicity in Aim 2.1 by treating with Doxorubicine, which causes gastrointestinal toxicity (mucositis) in patients, using multiple staining. The dose responses will be measured and analyzed using the MCP-Mod statistical- based method and compared to toxicity effects measure on human organoids, in Aim 2.2, to demonstrate the clinical relevance and the predictive nature of our approach. A streamlined protocol and chip fabrication pipeline for large-scale production will follow the development of a fully automated large-scale organoid screening platform. In Phase II, we will expand the chip to 96- and 384- well format for high-throughput and develop image analysis algorithm to handle a large volume of images generated from such phenotypic screens. Leveraging our unique expertise, Newormics will be able to sale OrganoidChipsTM to the consumer market and simultaneously have the organoid biobank to provide services with the large collection of canine-based organotypic models from multiple genetic backgrounds.
Science Code(s)/Area of Science(s) Primary: 72 - Predictive Toxicology/Assay Development
Publications No publications associated with this grant
Program Officer Daniel Shaughnessy
Back
to Top